CRDL Relative Valuation
CRDL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CRDL is overvalued; if below, it's undervalued.
Historical Valuation
Cardiol Therapeutics Inc (CRDL) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -4.07. The fair price of Cardiol Therapeutics Inc (CRDL) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：1.01
Fair
-3.29
PE
1Y
3Y
5Y
-4.43
EV/EBITDA
Cardiol Therapeutics Inc. (CRDL) has a current EV/EBITDA of -4.43. The 5-year average EV/EBITDA is -3.66. The thresholds are as follows: Strongly Undervalued below -9.33, Undervalued between -9.33 and -6.49, Fairly Valued between -0.83 and -6.49, Overvalued between -0.83 and 2.01, and Strongly Overvalued above 2.01. The current Forward EV/EBITDA of -4.43 falls within the Historic Trend Line -Fairly Valued range.
-3.27
EV/EBIT
Cardiol Therapeutics Inc. (CRDL) has a current EV/EBIT of -3.27. The 5-year average EV/EBIT is -3.27. The thresholds are as follows: Strongly Undervalued below -10.69, Undervalued between -10.69 and -6.98, Fairly Valued between 0.44 and -6.98, Overvalued between 0.44 and 4.15, and Strongly Overvalued above 4.15. The current Forward EV/EBIT of -3.27 falls within the Historic Trend Line -Fairly Valued range.
0.00
PS
Cardiol Therapeutics Inc. (CRDL) has a current PS of 0.00. The 5-year average PS is 23.36. The thresholds are as follows: Strongly Undervalued below -112.39, Undervalued between -112.39 and -44.51, Fairly Valued between 91.24 and -44.51, Overvalued between 91.24 and 159.12, and Strongly Overvalued above 159.12. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-5.54
P/OCF
Cardiol Therapeutics Inc. (CRDL) has a current P/OCF of -5.54. The 5-year average P/OCF is -5.66. The thresholds are as follows: Strongly Undervalued below -12.75, Undervalued between -12.75 and -9.20, Fairly Valued between -2.11 and -9.20, Overvalued between -2.11 and 1.44, and Strongly Overvalued above 1.44. The current Forward P/OCF of -5.54 falls within the Historic Trend Line -Fairly Valued range.
-6.22
P/FCF
Cardiol Therapeutics Inc. (CRDL) has a current P/FCF of -6.22. The 5-year average P/FCF is -5.98. The thresholds are as follows: Strongly Undervalued below -14.70, Undervalued between -14.70 and -10.34, Fairly Valued between -1.62 and -10.34, Overvalued between -1.62 and 2.74, and Strongly Overvalued above 2.74. The current Forward P/FCF of -6.22 falls within the Historic Trend Line -Fairly Valued range.
Cardiol Therapeutics Inc (CRDL) has a current Price-to-Book (P/B) ratio of 12.49. Compared to its 3-year average P/B ratio of 7.55 , the current P/B ratio is approximately 65.39% higher. Relative to its 5-year average P/B ratio of 6.14, the current P/B ratio is about 103.50% higher. Cardiol Therapeutics Inc (CRDL) has a Forward Free Cash Flow (FCF) yield of approximately -18.04%. Compared to its 3-year average FCF yield of -25.97%, the current FCF yield is approximately -30.54% lower. Relative to its 5-year average FCF yield of -23.03% , the current FCF yield is about -21.67% lower.
12.49
P/B
Median3y
7.55
Median5y
6.14
-18.04
FCF Yield
Median3y
-25.97
Median5y
-23.03
Competitors Valuation Multiple
The average P/S ratio for CRDL's competitors is 0.00, providing a benchmark for relative valuation. Cardiol Therapeutics Inc Corp (CRDL) exhibits a P/S ratio of 0.00, which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of CRDL increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of CRDL in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is Cardiol Therapeutics Inc (CRDL) currently overvalued or undervalued?
Cardiol Therapeutics Inc (CRDL) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -4.07. The fair price of Cardiol Therapeutics Inc (CRDL) is between to according to relative valuation methord.
What is Cardiol Therapeutics Inc (CRDL) fair value?
CRDL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Cardiol Therapeutics Inc (CRDL) is between to according to relative valuation methord.
How does CRDL's valuation metrics compare to the industry average?
The average P/S ratio for CRDL's competitors is 0.00, providing a benchmark for relative valuation. Cardiol Therapeutics Inc Corp (CRDL) exhibits a P/S ratio of 0.00, which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Cardiol Therapeutics Inc (CRDL) as of Jan 08 2026?
As of Jan 08 2026, Cardiol Therapeutics Inc (CRDL) has a P/B ratio of 12.49. This indicates that the market values CRDL at 12.49 times its book value.
What is the current FCF Yield for Cardiol Therapeutics Inc (CRDL) as of Jan 08 2026?
As of Jan 08 2026, Cardiol Therapeutics Inc (CRDL) has a FCF Yield of -18.04%. This means that for every dollar of Cardiol Therapeutics Inc’s market capitalization, the company generates -18.04 cents in free cash flow.
What is the current Forward P/E ratio for Cardiol Therapeutics Inc (CRDL) as of Jan 08 2026?
As of Jan 08 2026, Cardiol Therapeutics Inc (CRDL) has a Forward P/E ratio of -3.29. This means the market is willing to pay $-3.29 for every dollar of Cardiol Therapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Cardiol Therapeutics Inc (CRDL) as of Jan 08 2026?
As of Jan 08 2026, Cardiol Therapeutics Inc (CRDL) has a Forward P/S ratio of 0.00. This means the market is valuing CRDL at $0.00 for every dollar of expected revenue over the next 12 months.